Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets Er-Kim broadens drug distribution for novel rare endocrinology disease therapies in CEE and Eurasian markets

Er-Kim CEO Cem Zorlular Recognized as a Patient Champion on the 2024 PharmaVoice 100 Cem Zorlular, CEO of Er-Kim recognized as a patient champion in this year's PharmaVoice100

Er-Kim Selected to Join the World Economic Forum’s New Champions Community ATHENS, Greece, March 05, 2024 (GLOBE NEWSWIRE) -- Er-Kim, a pharmaceutical company specializing in the commercialization of novel therapies in international markets, announced today it has been...

Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey Er-Kim is appointed as the exclusive Ascendis A/S endocrinology distributor across Central & Eastern Europe and Turkey

Er-Kim Pharmaceuticals Supports Worldwide Prevention of Antimicrobial Resistance (AMR) Er-Kim Pharmaceuticals joins the industry to collaborate on the prevention of antimicrobial resistance (AMR) in support of World AMR Awareness Week